Apogee Therapeutics
APGE
157 hedge funds and large institutions have $2.62B invested in Apogee Therapeutics in 2024 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 55 increasing their positions, 40 reducing their positions, and 21 closing their positions.
90% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 21
38% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 40
13% more funds holding
Funds holding: 139 → 157 (+18)
3.87% more ownership
Funds ownership: 124.65% → 128.52% (+3.9%)
20% less capital invested
Capital invested by funds: $3.29B → $2.62B (-$671M)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
49% less call options, than puts
Call options by funds: $1.67M | Put options by funds: $3.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$38.1M |
| 2 |
Mercer Global Advisors
Denver,
Colorado
|
+$36.7M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$33.9M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
+$29.7M |
| 5 |
JFG
Jefferies Financial Group
New York
|
+$26.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$58.7M |
| 2 |
PA
Perceptive Advisors
New York
|
-$49.4M |
| 3 |
O
OrbiMed
New York
|
-$22.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.6M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$20M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
Credit Agricole
Montrouge Cedex,
France
| – | -$1.21K | -2,057 | Closed |
|
177
Bessemer Group
Woodbridge,
New Jersey
| – | -$2K | -30 | Closed |
|
|
CPA
178
Capital Performance Advisors
Walnut Creek,
California
| – | -$764 | -13 | Closed |
|
APGE Hedge Fund Activity: Q4 2024 in Review
157 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q4 2024, worth a combined $2.62B — down 20% from $3.29B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new APGE positions and 21 closed out — a net gain of 19 holders — while 55 added to existing stakes and 40 trimmed.
The largest buyer was Siren LLC, opening a new position worth an estimated $38.1M. The largest seller was Deep Track Capital, exiting entirely with an estimated $58.7M sold.
- 157 institutional investors held Apogee Therapeutics (APGE) as of Q4 2024, up from 139 in Q3 2024.
- Funds reported $2.62B of Apogee Therapeutics stock for Q4 2024, down 20% quarter-over-quarter.
- 40 funds opened new Apogee Therapeutics positions in Q4 2024 and 21 closed out, a net change of +19 holders.
- The largest Apogee Therapeutics buyer in Q4 2024 was Siren LLC, an estimated $38.1M added.
- The largest Apogee Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $58.7M sold.
Based on aggregated 13F filings for Q4 2024.